Top

Current Rheumatology Reports

Published in:

Open Access 01-09-2023 | Osteoarthrosis

The Potential Role of Probiotics in the Management of Osteoarthritis Pain: Current Status and Future Prospects

Authors: Syed Obaidur Rahman, Frédérique Bariguian, Ali Mobasheri

Published in: Current Rheumatology Reports | Issue 12/2023

Abstract

Purpose of Review

This narrative review article comprehensively explains the pathophysiology of osteoarthritis (OA) pain perception, how the gut microbiota is correlated with it, possible molecular pathways involved in probiotics-mediated OA pain reduction, limitations in the current research approaches, and future perspectives.

Recent Findings

The initiation and progression of OA, including the development of chronic pain, is intricately associated with activation of the innate immune system and subsequent inflammatory responses. Trauma, lifestyle (e.g., obesity and metabolic disease), and chronic antibiotic treatment can disrupt commensal homeostasis of the human microbiome, thereby affecting intestinal integrity and promoting leakage of bacterial endotoxins and metabolites such as lipopolysaccharides (LPS) into circulation. Increased level of LPS is associated with knee osteophyte severity and joint pain. Both preclinical and clinical studies strongly suggest that probiotics may benefit patients with OA pain through positive gut microbiota modulation and attenuating low-grade inflammation via multiple pathways. Patent data also suggests increased interest in the development of new innovations that involve probiotic use for reducing OA and joint pain.

Summary

Recent data suggest that probiotics are attracting more and more attention for OA pain management. The advancement of knowledge in this area may pave the way for developing different probiotic strains that can be used to support joint health, improve treatment outcomes in OA, and reduce the huge impact of the disease on healthcare systems worldwide.

Available only for authorised users

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(10159):1789–858. https://doi.org/10.1016/s0140-6736(18)32279-7.CrossRef

Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):293–311. https://doi.org/10.1016/j.mcna.2019.10.007.CrossRefPubMed

Terkawi MA, Ebata T, Yokota S, Takahashi D, Endo T, Matsumae G, et al. Low-grade inflammation in the pathogenesis of osteoarthritis: cellular and molecular mechanisms and strategies for future therapeutic intervention. Biomedicines. 2022;10(5). https://doi.org/10.3390/biomedicines10051109.

Woodell-May JE, Sommerfeld SD. Role of Inflammation and the immune system in the progression of osteoarthritis. J Orthopaedic Res : Off Publ Orthopaedic Res Soc. 2020;38(2):253–7. https://doi.org/10.1002/jor.24457.CrossRef

Miller RJ, Malfait AM, Miller RE. The innate immune response as a mediator of osteoarthritis pain. Osteoarthritis Cartilage. 2020;28(5):562–71. https://doi.org/10.1016/j.joca.2019.11.006.CrossRefPubMed

Durack J, Lynch SV. The gut microbiome: relationships with disease and opportunities for therapy. J Exp Med. 2019;216(1):20–40. https://doi.org/10.1084/jem.20180448.CrossRefPubMedPubMedCentral

Hao X, Shang X, Liu J, Chi R, Zhang J, Xu T. The gut microbiota in osteoarthritis: where do we stand and what can we do? Arthritis Res Ther. 2021;23(1):42. https://doi.org/10.1186/s13075-021-02427-9.CrossRefPubMedPubMedCentral

8.••

Guo R, Chen LH, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. British journal of anaesthesia. 2019;123(5):637–54. https://doi.org/10.1016/j.bja.2019.07.026. Reviews the role of the gut-microbiome and its metabolites in different types of chronic pain, including inflammatory pain, headache, neuropathic pain, and opioid tolerance.CrossRefPubMed

Lei M, Guo C, Wang D, Zhang C, Hua L. The effect of probiotic Lactobacillus casei Shirota on knee osteoarthritis: a randomised double-blind, placebo-controlled clinical trial. Beneficial Microbes. 2017;8(5):697–703. https://doi.org/10.3920/bm2016.0207.CrossRefPubMed

10.••

Lyu JL, Wang TM, Chen YH, Chang ST, Wu MS, Lin YH, et al. Oral intake of Streptococcus thermophil us improves knee osteoarthritis degeneration: a randomized, double-blind, placebo-controlled clinical study. Heliyon. 2020;6(4):e03757. https://doi.org/10.1016/j.heliyon.2020.e03757. A clinical study demonstrating that pain, stiffness, and joint function are not worsened even after 12 weeks of Streptococcus thermophilus treatment.CrossRefPubMedPubMedCentral

11.••

Taye I, Bradbury J, Grace S, Avila C. Probiotics for pain of osteoarthritis; an N-of-1 trial of individual effects. Complement Ther Med. 2020;54:102548. https://doi.org/10.1016/j.ctim.2020.102548. Lactobacillus rhamnosus, Saccharomyces cerevisiae, and Bifidobacterium animalis ssp. lactis combination lowered pain scores in a female with osteoarthritis.CrossRefPubMed

12.

Lee SH, Kwon JY, Jhun J, Jung K, Park SH, Yang CW, et al. Lactobacillus acidophilus ameliorates pain and cartilage degradation in experimental osteoarthritis. Immunol Lett. 2018;203:6–14. https://doi.org/10.1016/j.imlet.2018.07.003.CrossRefPubMed

13.

Cho KH, Na HS, Jhun J, Woo JS, Lee AR, Lee SY, et al. Lactobacillus (LA-1) and butyrate inhibit osteoarthritis by controlling autophagy and inflammatory cell death of chondrocytes. Front Immunol. 2022;13:930511. https://doi.org/10.3389/fimmu.2022.930511.CrossRefPubMedPubMedCentral

14.

Jhun J, Cho KH, Lee DH, Kwon JY, Woo JS, Kim J, et al. Oral administration of Lactobacillus rhamnosus ameliorates the progression of osteoarthritis by inhibiting joint pain and inflammation. Cells. 2021;10(5). https://doi.org/10.3390/cells10051057.

15.

So JS, Song MK, Kwon HK, Lee CG, Chae CS, Sahoo A, et al. Lactobacillus casei enhances type II collagen/glucosamine-mediated suppression of inflammatory responses in experimental osteoarthritis. Life Sci. 2011;88(7–8):358–66. https://doi.org/10.1016/j.lfs.2010.12.013.CrossRefPubMed

16.

Sim BY, Choi HJ, Kim MG, Jeong DG, Lee DG, Yoon JM, et al. Effects of ID-CBT5101 in preventing and alleviating osteoarthritis symptoms in a monosodium iodoacetate-induced rat model. J Microbiol Biotechnol. 2018;28(7):1199–208. https://doi.org/10.4014/jmb.1803.03032.CrossRefPubMed

17.

Chang SL, Lin YY, Liu SC, Tsai YS, Lin SW, Chen YL, et al. Oral administration of Clostridium butyricum GKB7 ameliorates signs of osteoarthritis in rats. Cells. 2022;11(14). https://doi.org/10.3390/cells11142169

18.

Lin YY, Chang SL, Liu SC, Achudhan D, Tsai YS, Lin SW, et al. Therapeutic effects of live Lactobacillus plantarum GKD7 in a rat model of knee osteoarthritis. Nutrients. 2022;14(15). https://doi.org/10.3390/nu14153170

19.

Lin YY, Chen NF, Yang SN, Jean YH, Kuo HM, Chen PC, et al. Effects of Streptococcus thermophilus on anterior cruciate ligament transection-induced early osteoarthritis in rats. Exp Ther Med. 2021;21(3):222. https://doi.org/10.3892/etm.2021.9653.CrossRefPubMedPubMedCentral

20.

I OS, Natarajan Anbazhagan A, Singh G, Ma K, Green SJ, Singhal M, et al. Lactobacillus acidophilus mitigates osteoarthritis-associated pain, cartilage disintegration and gut microbiota dysbiosis in an experimental murine OA model. Biomedicines. 2022;10(6). https://doi.org/10.3390/biomedicines10061298.

21.

Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263–7. https://doi.org/10.1136/ard.2004.025270.CrossRefPubMedPubMedCentral

22.

Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskeletal Dis. 2013;5(2):77–94. https://doi.org/10.1177/1759720x12467868.CrossRef

23.

Pauli C, Grogan SP, Patil S, Otsuki S, Hasegawa A, Koziol J, et al. Macroscopic and histopathologic analysis of human knee menisci in aging and osteoarthritis. Osteoarthritis Cartilage. 2011;19(9):1132–41. https://doi.org/10.1016/j.joca.2011.05.008.CrossRefPubMedPubMedCentral

24.

Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580–92. https://doi.org/10.1038/nrrheum.2016.136.CrossRefPubMedPubMedCentral

25.

Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015;23(11):1825–34. https://doi.org/10.1016/j.joca.2015.08.015.CrossRefPubMedPubMedCentral

26.

Gómez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G. TLR4 signalling in osteoarthritis–finding targets for candidate DMOADs. Nat Rev Rheumatol. 2015;11(3):159–70. https://doi.org/10.1038/nrrheum.2014.209.CrossRefPubMed

27.

Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune network. 2018;18(4):e27. https://doi.org/10.4110/in.2018.18.e27.CrossRefPubMedPubMedCentral

28.

Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13(11):460–9. https://doi.org/10.1016/j.molmed.2007.09.002.CrossRefPubMed

29.

Suantawee T, Tantavisut S, Adisakwattana S, Tanpowpong T, Tanavalee A, Yuktanandana P, et al. Upregulation of inducible nitric oxide synthase and nitrotyrosine expression in primary knee osteoarthritis. J Med Assoc Thailand Chotmaihet thangphaet. 2015;98(Suppl 1):S91-7.

30.

Liu YX, Wang GD, Wang X, Zhang YL, Zhang TL. Effects of TLR-2/NF-κB signaling pathway on the occurrence of degenerative knee osteoarthritis an in vivo and in vitro study. Oncotarget. 2017;8(24):38602–17. https://doi.org/10.18632/oncotarget.16199.CrossRefPubMedPubMedCentral

31.

Ostojic M, Zevrnja A, Vukojevic K, Soljic V. Immunofluorescence analysis of NF-kB and iNOS expression in different cell populations during early and advanced knee osteoarthritis. Int J Mole Sci. 2021;22(12). https://doi.org/10.3390/ijms22126461.

32.

Nedunchezhiyan U, Varughese I, Sun AR, Wu X, Crawford R, Prasadam I. Obesity, inflammation, and immune system in osteoarthritis. Frontiers in immunology. 2022;13:907750. https://doi.org/10.3389/fimmu.2022.907750.CrossRefPubMedPubMedCentral

33.

Smith JW, Martins TB, Gopez E, Johnson T, Hill HR, Rosenberg TD. Significance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes. Ther Adv Musculoskeletal Dis. 2012;4(5):315–25. https://doi.org/10.1177/1759720x12455959.CrossRef

34.

Snelling SJ, Bas S, Puskas GJ, Dakin SG, Suva D, Finckh A, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PloS one. 2017;12(4):e0175109. https://doi.org/10.1371/journal.pone.0175109.CrossRefPubMedPubMedCentral

35.

Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(5):516–23. https://doi.org/10.1016/j.joca.2006.10.010.CrossRefPubMed

36.•

Chisari E, Wouthuyzen-Bakker M, Friedrich AW, Parvizi J. The relation between the gut microbiome and osteoarthritis: a systematic review of literature. PloS one. 2021;16(12):e0261353. https://doi.org/10.1371/journal.pone.0261353. A systematic review of 19 preclinical and clinical studies explaining role of gut-joint axis in the pathogenesis and symptoms of OA.CrossRefPubMedPubMedCentral

37.

Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54. https://doi.org/10.1038/s41577-019-0198-4.CrossRefPubMed

38.

Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599–608. https://doi.org/10.1038/nrgastro.2012.152.CrossRefPubMed

39.

de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obesity Rev : Off J Int Assoc Study Obesity. 2011;12(6):449–58. https://doi.org/10.1111/j.1467-789X.2010.00845.x.CrossRef

40.

Anto L, Blesso CN. Interplay between diet, the gut microbiome, and atherosclerosis: role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism. J Nutri Biochem. 2022;105:108991. https://doi.org/10.1016/j.jnutbio.2022.108991.CrossRef

41.•

Tonelli Enrico V, Vo N, Methe B, Morris A, Sowa G. An unexpected connection: a narrative review of the associations between gut microbiome and musculoskeletal pain. Eur Spine J : Off Publ Eur Spine Soc, Eur Spinal Deform Soc, Eur Sect Cervical Spine Res Soc. 2022;31(12):3603–15. https://doi.org/10.1007/s00586-022-07429-y. The article highlights various metabolites of the gut microbiome that play a pivotal role in musculoskeletal health.CrossRef

42.

Guo S, Al-Sadi R, Said HM, Ma TY. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol. 2013;182(2):375–87. https://doi.org/10.1016/j.ajpath.2012.10.014.CrossRefPubMedPubMedCentral

43.

Huang Z, Kraus VB. Does lipopolysaccharide-mediated inflammation have a role in OA? Nat Rev Rheumatol. 2016;12(2):123–9. https://doi.org/10.1038/nrrheum.2015.158.CrossRefPubMed

44.

Tanaka S, Toki T, Akimoto T, Morishita K. Lipopolysaccharide accelerates collagen-induced arthritis in association with rapid and continuous production of inflammatory mediators and anti-type II collagen antibody. Microbiol Immunol. 2013;57(6):445–54. https://doi.org/10.1111/1348-0421.12052.CrossRefPubMed

45.

Islam MR, Arthur S, Haynes J, Butts MR, Nepal N, Sundaram U. The role of gut microbiota and metabolites in obesity-associated chronic gastrointestinal disorders. Nutrients. 2022;14(3). https://doi.org/10.3390/nu14030624.

46.

Rohr MW, Narasimhulu CA, Rudeski-Rohr TA, Parthasarathy S. Negative effects of a high-fat diet on intestinal permeability: a review. Adv Nutri (Bethesda, Md). 2020;11(1):77–91. https://doi.org/10.1093/advances/nmz061.CrossRef

47.

Metcalfe D, Harte AL, Aletrari MO, Al Daghri NM, Al Disi D, Tripathi G, et al. Does endotoxaemia contribute to osteoarthritis in obese patients? Clin Sci (London England: 1979). 2012;123(11):627–34. https://doi.org/10.1042/cs20120073.CrossRef

48.

Chen Y, Jiang W, Yong H, He M, Yang Y, Deng Z, et al. Macrophages in osteoarthritis: pathophysiology and therapeutics. Am J Trans Res. 2020;12(1):261–8.

49.

Bode JG, Ehlting C, Häussinger D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal. 2012;24(6):1185–94. https://doi.org/10.1016/j.cellsig.2012.01.018.CrossRefPubMed

50.

Mendez ME, Murugesh DK, Sebastian A, Hum NR, McCloy SA, Kuhn EA, et al. Antibiotic treatment prior to injury improves post-traumatic osteoarthritis outcomes in mice. International journal of molecular sciences. 2020;21(17). https://doi.org/10.3390/ijms21176424.

51.••

Guan Z, Jia J, Zhang C, Sun T, Zhang W, Yuan W, et al. Gut microbiome dysbiosis alleviates the progression of osteoarthritis in mice. Clinical science (London, England : 1979). 2020;134(23):3159–74. https://doi.org/10.1042/cs20201224. The antibiotic-induced intestinal microbiota dysbiosis reduced the serum level of lipopolysaccharide and the inflammatory response in a mouse model of osteoarthritis.CrossRefPubMed

52.

Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O’Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum. 1992;35(10):1150–9. https://doi.org/10.1002/art.1780351007.CrossRefPubMed

53.

Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005;52(7):2015–25. https://doi.org/10.1002/art.21122.CrossRefPubMed

54.

Hameed S. Na(v)1.7 and Na(v)1.8: Role in the pathophysiology of pain. Mole Pain. 2019;15:1744806919858801. https://doi.org/10.1177/1744806919858801.CrossRef

55.

Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci USA. 2012;109(50):20602–7. https://doi.org/10.1073/pnas.1209294110.CrossRefPubMedPubMedCentral

56.

Fingleton C, Smart K, Moloney N, Fullen BM, Doody C. Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(7):1043–56. https://doi.org/10.1016/j.joca.2015.02.163.CrossRefPubMed

57.

Höper J, Schraml L, Gierthmühlen J, Helfert SM, Rehm S, Härtig S, et al. Changes of somatosensory phenotype in the course of disease in osteoarthritis patients. International journal of environmental research and public health. 2020;17(9). https://doi.org/10.3390/ijerph17093085.

58.••

Morreale C, Bresesti I, Bosi A, Baj A, Giaroni C, Agosti M, et al. Microbiota and pain: save your gut feeling. Cells. 2022;11(6). https://doi.org/10.3390/cells11060971. A recent and important review highlighting role of gut-brain axis and efficacy of probiotics in different pain disorders.

59.

Diogenes A, Ferraz CC, Akopian AN, Henry MA, Hargreaves KM. LPS sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. J Dent Res. 2011;90(6):759–64. https://doi.org/10.1177/0022034511400225.CrossRefPubMed

60.

Qi J, Buzas K, Fan H, Cohen JI, Wang K, Mont E, et al. Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J Immunol (Baltimore, Md : 1950). 2011;186(11):6417–26. https://doi.org/10.4049/jimmunol.1001241.CrossRef

61.

Meseguer V, Alpizar YA, Luis E, Tajada S, Denlinger B, Fajardo O, et al. TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins. Nat Commun. 2014;5:3125. https://doi.org/10.1038/ncomms4125.CrossRefPubMed

62.

Chen G, Zhang YQ, Qadri YJ, Serhan CN, Ji RR. Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain. Neuron. 2018;100(6):1292–311. https://doi.org/10.1016/j.neuron.2018.11.009.CrossRefPubMedPubMedCentral

63.

Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56–68. https://doi.org/10.1016/j.pharmthera.2010.01.002.CrossRefPubMedPubMedCentral

64.

Matsuda M, Huh Y, Ji RR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J Anesth. 2019;33(1):131–9. https://doi.org/10.1007/s00540-018-2579-4.CrossRefPubMed

65.

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926. https://doi.org/10.1016/j.jpain.2009.06.012.CrossRefPubMedPubMedCentral

66.

Abdel-Haq R, Schlachetzki JCM, Glass CK, Mazmanian SK. Microbiome-microglia connections via the gut-brain axis. J Exp Med. 2019;216(1):41–59. https://doi.org/10.1084/jem.20180794.CrossRefPubMedPubMedCentral

67.

Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965–77. https://doi.org/10.1038/nn.4030.CrossRefPubMedPubMedCentral

68.•

Dahshan D, Gallagher N, Workman A, Perdue J, Aikens J, Schmicker T, et al. Targeting the gut microbiome for inflammation and pain management in orthopedic conditions. Orthopedics. 2022;45(5):e226–34. https://doi.org/10.3928/01477447-20220608-07. A review highlighting the effect of gut microbiome on pain and inflammatory markers associated with osteoarthritis, rheumatoid arthritis, fractures/osteoporosis, and bone pain associated with chemotherapy.CrossRefPubMed

69.

Amaral FA, Sachs D, Costa VV, Fagundes CT, Cisalpino D, Cunha TM, et al. Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci USA. 2008;105(6):2193–7. https://doi.org/10.1073/pnas.0711891105.CrossRefPubMedPubMedCentral

70.

Yan S, Kentner AC. Mechanical allodynia corresponds to Oprm1 downregulation within the descending pain network of male and female rats exposed to neonatal immune challenge. Brain Behav Immun. 2017;63:148–59. https://doi.org/10.1016/j.bbi.2016.10.007.CrossRefPubMed

71.

Vieira AT, Macia L, Galvão I, Martins FS, Canesso MC, Amaral FA, et al. A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol (Hoboken, NJ). 2015;67(6):1646–56. https://doi.org/10.1002/art.39107.CrossRef

72.••

Sánchez Romero EA, Meléndez Oliva E, Alonso Pérez JL, Martín Pérez S, Turroni S, Marchese L, et al. Relationship between the gut microbiome and osteoarthritis pain: review of the literature. Nutrients. 2021;13(3). https://doi.org/10.3390/nu13030716. A systematic review highlighting how dysbiosis and a proinflammatory microbiome profile in OA patients might play a role in the severity of symptoms, particularly pain.

73.

Boer CG, Radjabzadeh D, Medina-Gomez C, Garmaeva S, Schiphof D, Arp P, et al. Intestinal microbiome composition and its relation to joint pain and inflammation. Nat Commun. 2019;10(1):4881. https://doi.org/10.1038/s41467-019-12873-4.CrossRefPubMedPubMedCentral

74.

Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–27. https://doi.org/10.1016/j.immuni.2010.06.001.CrossRefPubMedPubMedCentral

75.

Huang ZY, Stabler T, Pei FX, Kraus VB. Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthritis Cartilage. 2016;24(10):1769–75. https://doi.org/10.1016/j.joca.2016.05.008.CrossRefPubMedPubMedCentral

76.••

Dunn CM, Velasco C, Rivas A, Andrews M, Garman C, Jacob PB, et al. Identification of cartilage microbial DNA signatures and associations with knee and hip osteoarthritis. Arthritis & rheumatology (Hoboken, NJ). 2020;72(7):1111–22. https://doi.org/10.1002/art.41210. A study conducted in osteoarthritis patients providing the first evidence of microbial DNA signature in human cartilage and substantial increase in gram-negative constituents as well as lipopolysaccharide biosynthesis.CrossRef

77.•

Favazzo LJ, Hendesi H, Villani DA, Soniwala S, Dar QA, Schott EM, et al. The gut microbiome-joint connection: implications in osteoarthritis. Curr Opin Rheumatol. 2020;32(1):92–101. https://doi.org/10.1097/bor.0000000000000681. Review of evidence examining the link between the gut microbiome and joint with special focus on osteoarthritis.CrossRefPubMed

78.

Wieërs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy JM, Dequenne I, et al. How probiotics affect the microbiota. Front Cell Infect Microbiol. 2019;9:454. https://doi.org/10.3389/fcimb.2019.00454.CrossRefPubMed

79.

Han S, Lu Y, Xie J, Fei Y, Zheng G, Wang Z, et al. Probiotic gastrointestinal transit and colonization after oral administration: a long journey. Front Cell Infect Microbiol. 2021;11:609722. https://doi.org/10.3389/fcimb.2021.609722.CrossRefPubMedPubMedCentral

80.••

Zeng L, Deng Y, He Q, Yang K, Li J, Xiang W, et al. Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: a systematic review and meta-analysis of 34 randomized controlled trials. Front Immunol. 2022;13:961325. https://doi.org/10.3389/fimmu.2022.961325. A recent pooled analysis of randomized controlled trials revealing that probiotic supplements might improve inflammatory arthritis.CrossRefPubMedPubMedCentral

81.

Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61; quiz 6, 62. https://doi.org/10.1038/ajg.2014.202.

82.

McVey Neufeld KA, Strain CR, Pusceddu MM, Waworuntu RV, Manurung S, Gross G, et al. Lactobacillus rhamnosus GG soluble mediators ameliorate early life stress-induced visceral hypersensitivity and changes in spinal cord gene expression. Neuronal Signal. 2020;4(4):Ns20200007. https://doi.org/10.1042/ns20200007.CrossRefPubMedPubMedCentral

83.

Cuozzo M, Castelli V, Avagliano C, Cimini A, d’Angelo M, Cristiano C, et al. Effects of chronic oral probiotic treatment in paclitaxel-induced neuropathic pain. Biomedicines. 2021;9(4). https://doi.org/10.3390/biomedicines9040346.

84.

Ding W, You Z, Chen Q, Yang L, Doheny J, Zhou X, et al. Gut microbiota influences neuropathic pain through modulating proinflammatory and anti-inflammatory T cells. Anesth Analg. 2021;132(4):1146–55. https://doi.org/10.1213/ane.0000000000005155.CrossRefPubMed

85.

Banjonjit S, Taweechotipatr M, Rungsiyanont S. Effect of probiotic Lactobacillus paracasei on tumor necrosis factor-alpha level in gingival crevicular fluid of patients undergoing impacted third molar removal. J Oral Sci. 2022;64(3):185–9. https://doi.org/10.2334/josnusd.21-0457.CrossRefPubMed

86.

Ferrés-Amat E, Espadaler-Mazo J, Calvo-Guirado JL, Ferrés-Amat E, Mareque-Bueno J, Salavert A, et al. Probiotics diminish the post-operatory pain following mandibular third molar extraction: a randomised double-blind controlled trial (pilot study). Beneficial Microbes. 2020;11(7):631–9. https://doi.org/10.3920/bm2020.0090.CrossRefPubMed

87.

Wälivaara D, Sjögren I, Gerasimcik N, Yucel-Lindberg T, Twetman S, Abrahamsson P. Effects of Lactobacillus reuteri-containing lozenges on healing after surgical removal of mandibular third molars: a randomised controlled trial. Beneficial Microbes. 2019;10(6):653–9. https://doi.org/10.3920/bm2018.0168.CrossRefPubMed

88.

Jensen OK, Andersen MH, Østgård RD, Andersen NT, Rolving N. Probiotics for chronic low back pain with type 1 Modic changes: a randomized double-blind, placebo-controlled trial with 1-year follow-up using Lactobacillus Rhamnosis GG. Eur Spine J : Off Publ Eur Spine Soc, Eur Spinal Deform Soc, Eur Sect Cervical Spine Res Soc. 2019;28(11):2478–86. https://doi.org/10.1007/s00586-019-06046-6.CrossRef

89.

Itoh H, Uchida M, Sashihara T, Ji ZS, Li J, Tang Q, et al. Lactobacillus gasseri OLL2809 is effective especially on the menstrual pain and dysmenorrhea in endometriosis patients: randomized, double-blind, placebo-controlled study. Cytotechnology. 2011;63(2):153–61. https://doi.org/10.1007/s10616-010-9326-5.CrossRefPubMed

90.

Khodaverdi S, Mohammadbeigi R, Khaledi M, Mesdaghinia L, Sharifzadeh F, Nasiripour S, et al. Beneficial effects of oral lactobacillus on pain severity in women suffering from endometriosis: a pilot placebo-controlled randomized clinical trial. Int J Fertil Steril. 2019;13(3):178–83. https://doi.org/10.22074/ijfs.2019.5584.CrossRefPubMedPubMedCentral

91.

Ghavami A, Khorvash F, Heidari Z, Khalesi S, Askari G. Effect of synbiotic supplementation on migraine characteristics and inflammatory biomarkers in women with migraine: results of a randomized controlled trial. Pharmacol Res. 2021;169:105668. https://doi.org/10.1016/j.phrs.2021.105668.CrossRefPubMed

92.

Martami F, Togha M, Seifishahpar M, Ghorbani Z, Ansari H, Karimi T, et al. The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: a randomized double-blind controlled trial. Cephalalgia : Int J Headache. 2019;39(7):841–53. https://doi.org/10.1177/0333102418820102.CrossRef

93.

Qi X, Fan G, Jia H. The probiotic Lactobacillus casei Shirota attenuates symptoms of vestibular migraine: a randomised placebo-controlled double-blind clinical trial. Beneficial Microbes. 2020;11(5):469–76. https://doi.org/10.3920/bm2020.0058.CrossRefPubMed

94.

Hill D, Sugrue I, Tobin C, Hill C, Stanton C, Ross RP. The Lactobacillus casei group: history and health related applications. Front Microbiol. 2018;9:2107. https://doi.org/10.3389/fmicb.2018.02107.CrossRefPubMedPubMedCentral

95.

Amdekar S, Singh V, Singh R, Sharma P, Keshav P, Kumar A. Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol. 2011;31(2):147–54. https://doi.org/10.1007/s10875-010-9457-7.CrossRefPubMed

96.

Takano S, Uchida K, Inoue G, Minatani A, Miyagi M, Aikawa J, et al. Increase and regulation of synovial calcitonin gene-related peptide expression in patients with painful knee osteoarthritis. J Pain Res. 2017;10:1099–104. https://doi.org/10.2147/jpr.S135939.CrossRefPubMedPubMedCentral

97.

Pajak A, Kostrzewa M, Malek N, Korostynski M, Starowicz K. Expression of matrix metalloproteinases and components of the endocannabinoid system in the knee joint are associated with biphasic pain progression in a rat model of osteoarthritis. J Pain Res. 2017;10:1973–89. https://doi.org/10.2147/jpr.S132682.CrossRefPubMedPubMedCentral

98.

Farrajota K, Cheng S, Martel-Pelletier J, Afif H, Pelletier JP, Li X, et al. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta 12,14-prostaglandin J2 through a histone deacetylase-independent mechanism. Arthritis Rheum. 2005;52(1):94–104. https://doi.org/10.1002/art.20714.CrossRefPubMed

99.

Giaginis C, Giagini A, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res. 2009;60(3):160–9. https://doi.org/10.1016/j.phrs.2009.02.005.CrossRefPubMed

100.

Reckziegel D, Raschke F, Cottam WJ, Auer DP. Cingulate GABA levels inversely correlate with the intensity of ongoing chronic knee osteoarthritis pain. Mole Pain. 2016;12. https://doi.org/10.1177/1744806916650690.

101.

Fernihough J, Gentry C, Bevan S, Winter J. Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett. 2005;388(2):75–80. https://doi.org/10.1016/j.neulet.2005.06.044.CrossRefPubMed

102.

Grässel SG. The role of peripheral nerve fibers and their neurotransmitters in cartilage and bone physiology and pathophysiology. Arthritis Res Ther. 2014;16(6):485. https://doi.org/10.1186/s13075-014-0485-1.CrossRefPubMedPubMedCentral

103.

Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutrients. 2020;12(4). https://doi.org/10.3390/nu12041107.

104.

Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16(6):341–52. https://doi.org/10.1038/nri.2016.42.CrossRefPubMedPubMedCentral

105.

Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The controversial role of human gut Lachnospiraceae. Microorganisms. 2020;8(4). https://doi.org/10.3390/microorganisms8040573

106.

Hashizume M, Koike N, Yoshida H, Suzuki M, Mihara M. High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis. Mod Rheumatol. 2010;20(5):432–8. https://doi.org/10.1007/s10165-010-0299-1.CrossRefPubMed

107.

Monticone M, Frizziero A, Rovere G, Vittadini F, Uliano D, Lab S, et al. Hyaluronic acid intra-articular injection and exercise therapy: effects on pain and disability in subjects affected by lower limb joints osteoarthritis A systematic review by the Italian Society of Physical and Rehabilitation Medicine (SIMFER). Eur J Phys Rehabilitat Med. 2016;52(3):389–99.

108.

Kato-Kataoka A, Nishida K, Takada M, Kawai M, Kikuchi-Hayakawa H, Suda K, et al. Fermented milk containing Lactobacillus casei strain Shirota preserves the diversity of the gut microbiota and relieves abdominal dysfunction in healthy medical students exposed to academic stress. Appl Environ Microbiol. 2016;82(12):3649–58. https://doi.org/10.1128/aem.04134-15.CrossRefPubMedPubMedCentral

109.

Jin X, Beguerie JR, Zhang W, Blizzard L, Otahal P, Jones G, et al. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(4):703–10. https://doi.org/10.1136/annrheumdis-2013-204494.CrossRefPubMed

110.•

Tan TC, Chong TKY, Low AHL, Leung YY. Microbiome and osteoarthritis: new insights from animal and human studies. Int J Rheum Dis. 2021;24(8):984–1003. https://doi.org/10.1111/1756-185x.14123. Review of preclinical and clinical studies demonstrating association of gut microbiome and osteoarthritis.CrossRefPubMed

111.

Bagraith KS, Strong J, Meredith PJ, McPhail SM. What do clinicians consider when assessing chronic low back pain? A content analysis of multidisciplinary pain centre team assessments of functioning, disability, and health. Pain. 2018;159(10):2128–36. https://doi.org/10.1097/j.pain.0000000000001285.CrossRefPubMed

112.

Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society Results from a workshop. Osteoarthritis Cartilage. 1996;4(4):217–43. https://doi.org/10.1016/s1063-4584(05)80101-3.CrossRefPubMed

113.

Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis Consensus development at OMERACT III. J Rheumatol. 1997;24(4):799–802.PubMed

114.

Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–55. https://doi.org/10.1136/ard.2003.011742.CrossRefPubMedPubMedCentral

115.

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, et al. The OMERACT-OARSI core domain set for measurement in clinical trials of hip and/or knee osteoarthritis. J Rheumatol. 2019;46(8):981–9. https://doi.org/10.3899/jrheum.181194.CrossRefPubMed

116.

Yu XH, Yang YQ, Cao RR, Bo L, Lei SF. The causal role of gut microbiota in development of osteoarthritis. Osteoarthritis Cartilage. 2021;29(12):1741–50. https://doi.org/10.1016/j.joca.2021.08.003.CrossRefPubMed

Title: The Potential Role of Probiotics in the Management of Osteoarthritis Pain: Current Status and Future Prospects
Authors: Syed Obaidur Rahman
Frédérique Bariguian
Ali Mobasheri
Publication date: 01-09-2023
Publisher: Springer US
Keywords: Osteoarthrosis
Osteoarthrosis
Probiotics
Respiratory Microbiota
Published in: Current Rheumatology Reports / Issue 12/2023
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-023-01108-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2023

HLA-B*27 and Ankylosing Spondylitis: 50 Years of Insights and Discoveries

Digital Approaches for Myositis

Definition, presentation, and management of difficult-to-treat rheumatoid arthritis

The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review

Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature

How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage